Netabolics

Artificial Intelligence & Digital Twin for Drug Discovery

Avoid unnecessary preclinical tests with in silico target validation

THE COMPANY

Netabolics Life in Silico

Netabolics is an AI-driven Biotech company. We have an extensive and multidisciplinary experience in both theoretical and experimental study of cell metabolism. Our team includes life scientists and software engineers working collaboratively to produce the best and cost-effective computational methods for simulating the metabolic machinery of life.

We focus on metabolism because it is the surrogate of an organism's phenotype. As the saying goes: genome is what can happen, transcriptome is what appears to be happening, proteome is what makes it happen, and metabolome is what actually happens. Our discovery platform helps in predicting the metabolic changes occurring inside any cell type in response to pharmacological, genetic and environmental factors — in real-time.

Mauro DiNuzzo, Founder & CEO

Our mission is to make the process of drug discovery faster, cheaper and more efficient.

We have an international network of academic and industrial partners, collaborating research laboratories, and customers that trust our technology. We constantly seek mission-aligned partners to advance our discovery platform.

THE TEAM

Mauro DiNuzzo

Founder & CEO

Federico Giove

CSO

Emilio De Lazzari

CTO

Matteo Gustinetti

CFO

Bob Bastian

COO

Francesco Iamurri

CMO

We accelerate the Research & Development process of Pharma and Biotech for the benefit of people

THE TECHNOLOGY

Where AI Meets Digital Twin

Our discovery platform couples enzyme kinetics with branches of deep reinforcement learning overlaid onto first principles of physics and biology to address problems and unmet needs in the real-time simulation of genome-scale metabolic networks.

By leveraging artificial intelligence and digital twin prototyping, we develop digital replicas of human cells and offer a cloud platform to conduct computational simulations for predicting the effect of new drugs on cellular metabolism.

Learn how Artificial Intelligence empowers modeling and dynamical simulation of cell metabolism

Here we show our predictive analysis on a model system of human erythrocyte (red blood cell) metabolism.

THE SCIENCE

Our proprietary algorithms are rooted in biochemistry and are incorporated in a suite of powerful computational tools based on artificial intelligence that ensure full compliance with non-equilibrium thermodynamics across the entire modeling pipeline.

Kinetic models are the ultimate tools for simulating biochemistry because they can predict exact quantities for any variable in the system, thereby making the implementation of single-cell or multicellular digital twin possible.

THE PLATFORM

Target Validation in the Cloud

We strive to provide in silico solutions for drug discovery for both industry and academia. Find out how your R&D gets value from day one. Our AI-powered cloud-computing platform is cost-effective and always up-to-date.

Use the Netabolics platform to turn knowledge into testable predictions. Design your next experiment. Learn from informative data. Iterate.

DRUG TO MARKET

Drug

0 +

Years

Billion USD

0 %

Failure Rate

Inadequate or Lack of Efficacy

30-55%

High Toxicity or Safety Issues

15-35%

Not sure about our Discovery Platform? Don't trust us. Request a Demo.

Gain insights into metabolic pathway optimization, target identification/validation, biomarker determination, and more for Drug Discovery, Synthetic Biology, Precision Medicine, as well as Basic and Translational Research.

Please send us a message if you want to stay in the loop

This project received funding from the European Regional Development Fund Pre-Seed Regione Lazio POR-FESR 2014-2020

Netabolics S.R.L.
Circonvallazione Ostiense 229, 00154 Rome, Italy
VAT: IT-15768861005 | REA: RM-1612733

COOKIE POLICY PRIVACY POLICY TERMS OF USE